In 1985, as a partnership between the American Cancer Society and the pharmaceutical division of Imperial Chemical Industries (now part of AstraZeneca), October was officially observed for the first time as National Breast Cancer Awareness Month.
In observation of the deadly condition, people are encouraged to wear pink to raise awareness.
October, however, is also Liver Cancer Awareness month, and the Fibrolamellar Cancer Foundation (FCF) is using the color green to make sure that the fifth most common cancer type in the world is properly recognized.
"Unfortunately, there are more types of cancer than there are months of the year," John Hopper, President of the Greenwich-CT based FCF and Co-Chair of the GI Cancers Alliance (GICA) said in a press release. "Since Fibrolamellar is such a rare and aggressive cancer, Liver Cancer Awareness Month creates an important opportunity to spread the word about the great need for research funding.”
The American Cancer Society
estimates that more than 40,000 new cases of liver and intrahepatic bile duct cancer will be diagnosed in 2017, and that nearly 30,000 will die because of these conditions. The FCF is partnering with more than a dozen prominent research institutions, including the National Cancer Institute (NCI) in an effort to discover new therapies.
Additionally, the FCF will be hosting its second annual research gathering, Fibrolamellar Research Summit - Building a Roadmap Toward a Cure
, November 1-2 in Stamford, Connecticut. The summit will provide an important forum for concerted exchange among some of the world’s most renown GI cancer doctors.
"Research for treatments or cures for all cancers are a united goal," Hopper said. "We’re all invested in doing everything we can in the battle against cancer."
MDs and PhDs who are looking to attend the Summit can visit the event page
. To learn more about the FCF, visit the Foundation’s official website: http://fibrofoundation.org/
To learn more about liver cancer and other types of rare cancers, follow Rare Disease Report